19509141

Source:http://linkedlifedata.com/resource/pubmed/id/19509141

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001807, umls-concept:C0013206, umls-concept:C0035647, umls-concept:C0301625, umls-concept:C0334227, umls-concept:C0373483, umls-concept:C0376358, umls-concept:C0388088, umls-concept:C1419771, umls-concept:C1548848, umls-concept:C1710360
pubmed:issue	13
pubmed:dateCreated	2009-7-2
pubmed:abstractText	Previously, FTY720 was found to possess potent anticancer effects on various types of cancer. In the present study, we aimed to first verify the role of Runx2 in prostate cancer progression and metastasis, and, subsequently, assessed if FTY720 could modulate Runx2 expression, thus interfering downstream events regulated by this protein.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Androgens, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Core Binding Factor Alpha 1 Subunit, http://linkedlifedata.com/resource/pubmed/chemical/Propylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/RUNX2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Sphingosine, http://linkedlifedata.com/resource/pubmed/chemical/fingolimod
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1078-0432
pubmed:author	pubmed-author:ChanKwok-WahKW, pubmed-author:ChiuYung-TuenYT, pubmed-author:ChuaChee-WaiCW, pubmed-author:LingMing-TatMT, pubmed-author:ManKwanK, pubmed-author:WangXianghongX, pubmed-author:WongYong-ChuanYC, pubmed-author:YuenHiu-FungHF
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	15
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4322-35
pubmed:meshHeading	pubmed-meshheading:19509141-Aged, pubmed-meshheading:19509141-Aged, 80 and over, pubmed-meshheading:19509141-Androgens, pubmed-meshheading:19509141-Antineoplastic Agents, pubmed-meshheading:19509141-Case-Control Studies, pubmed-meshheading:19509141-Core Binding Factor Alpha 1 Subunit, pubmed-meshheading:19509141-Down-Regulation, pubmed-meshheading:19509141-Drug Resistance, Neoplasm, pubmed-meshheading:19509141-Drug Screening Assays, Antitumor, pubmed-meshheading:19509141-Gene Expression Regulation, Neoplastic, pubmed-meshheading:19509141-Humans, pubmed-meshheading:19509141-Male, pubmed-meshheading:19509141-Middle Aged, pubmed-meshheading:19509141-Neoplasm Invasiveness, pubmed-meshheading:19509141-Neoplasm Metastasis, pubmed-meshheading:19509141-Propylene Glycols, pubmed-meshheading:19509141-Prostatic Intraepithelial Neoplasia, pubmed-meshheading:19509141-Prostatic Neoplasms, pubmed-meshheading:19509141-Sphingosine, pubmed-meshheading:19509141-Tumor Cells, Cultured
pubmed:year	2009
pubmed:articleTitle	Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
pubmed:affiliation	Cancer Biology Group, Department of Anatomy and Departments of Pathology and Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Validation Studies